SCHEMBL18179939

SCHEMBL18179939

CN(C(=O)[C@@H](N)Cc1cc(F)cc(F)c1)c1ccc2sncc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM5 Q9NZQ8 5/20 0.39
CIT O14578 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
CLK1 P49759 1/20 0.32
CLK2 P49760 1/20 0.32
DYRK1A Q13627 1/20 0.32
CDC7 O00311 1/20 0.32
PLK4 O00444 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32
PIM1 P11309 1/20 0.32
PRKACA P17612 1/20 0.32
AXL P30530 1/20 0.32
CSNK1D P48730 1/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
RPS6KA3 P51812 1/20 0.32
CSNK2A1 P68400 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18171829 0.85 TRPM5 (0.38) TRPM5CDC7PLK4AURKADAPK3
SCHEMBL18180208 0.82 MAPT (0.42) CITAKT1AKT2AKT3
SCHEMBL19951484 0.81 TRPM5 (0.35) TRPM5CDC7PLK4AURKADAPK3
SCHEMBL19951482 0.81 TRPM5 (0.35) TRPM5CDC7PLK4AURKADAPK3
SCHEMBL19969184 0.80 DYRK1A (0.35) CITAAK1CLK1CLK2DYRK1A
SCHEMBL18173873 0.80 ALDH1A1 (0.41) CITCLK1CLK2DYRK1A
SCHEMBL18173872 0.80 ALDH1A1 (0.41) CITCLK1CLK2DYRK1A
SCHEMBL21992599 0.80 DYRK1A (0.35) CITAAK1CLK1CLK2DYRK1A
SCHEMBL19951483 0.80 CTSS (0.41) TRPM5
SCHEMBL16669965 0.79 CIT (0.36) CITAAK1CLK1CLK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed
WO-2016172425-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E TRPM5 4731/4885CIT 1229/4885AAK1 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.